NASDAQ:ODT

Odonate Therapeutics Competitors

$3.85
+0.33 (+9.38 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.40
Now: $3.85
$4.06
50-Day Range
$3.09
MA: $13.94
$24.28
52-Week Range
$3.02
Now: $3.85
$46.50
Volume12.23 million shs
Average Volume3.87 million shs
Market Capitalization$148.63 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66

Competitors

Odonate Therapeutics (NASDAQ:ODT) Vs. EOLS, RLMD, ANAB, ALDX, MRNS, and CRNX

Should you be buying ODT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Odonate Therapeutics, including Evolus (EOLS), Relmada Therapeutics (RLMD), AnaptysBio (ANAB), Aldeyra Therapeutics (ALDX), Marinus Pharmaceuticals (MRNS), and Crinetics Pharmaceuticals (CRNX).

Evolus (NASDAQ:EOLS) and Odonate Therapeutics (NASDAQ:ODT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Odonate Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Insider and Institutional Ownership

21.7% of Evolus shares are held by institutional investors. Comparatively, 96.0% of Odonate Therapeutics shares are held by institutional investors. 10.1% of Evolus shares are held by insiders. Comparatively, 48.9% of Odonate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Evolus and Odonate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
Odonate TherapeuticsN/A-85.75%-71.45%

Earnings & Valuation

This table compares Evolus and Odonate Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26
Odonate TherapeuticsN/AN/A$-111,820,000.00($4.05)-0.95

Evolus has higher revenue and earnings than Odonate Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Odonate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Evolus and Odonate Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
Odonate Therapeutics13102.00

Evolus currently has a consensus price target of $13.8889, indicating a potential upside of 2.27%. Odonate Therapeutics has a consensus price target of $19.3333, indicating a potential upside of 402.16%. Given Odonate Therapeutics' higher possible upside, analysts plainly believe Odonate Therapeutics is more favorable than Evolus.

Summary

Evolus beats Odonate Therapeutics on 7 of the 13 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Odonate Therapeutics (NASDAQ:ODT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk & Volatility

Relmada Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Odonate Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Institutional and Insider Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Odonate Therapeutics shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Comparatively, 48.9% of Odonate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Relmada Therapeutics and Odonate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
Odonate TherapeuticsN/A-85.75%-71.45%

Earnings and Valuation

This table compares Relmada Therapeutics and Odonate Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-16.31
Odonate TherapeuticsN/AN/A$-111,820,000.00($4.05)-0.95

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Odonate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Relmada Therapeutics and Odonate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Odonate Therapeutics13102.00

Relmada Therapeutics currently has a consensus target price of $63.3333, indicating a potential upside of 79.77%. Odonate Therapeutics has a consensus target price of $19.3333, indicating a potential upside of 402.16%. Given Odonate Therapeutics' higher possible upside, analysts plainly believe Odonate Therapeutics is more favorable than Relmada Therapeutics.

AnaptysBio (NASDAQ:ANAB) and Odonate Therapeutics (NASDAQ:ODT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk & Volatility

AnaptysBio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Odonate Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Institutional and Insider Ownership

96.0% of Odonate Therapeutics shares are held by institutional investors. 13.0% of AnaptysBio shares are held by company insiders. Comparatively, 48.9% of Odonate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares AnaptysBio and Odonate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Odonate TherapeuticsN/A-85.75%-71.45%

Earnings and Valuation

This table compares AnaptysBio and Odonate Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million71.39$-97,340,000.00($3.60)-5.80
Odonate TherapeuticsN/AN/A$-111,820,000.00($4.05)-0.95

AnaptysBio has higher revenue and earnings than Odonate Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Odonate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for AnaptysBio and Odonate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Odonate Therapeutics13102.00

AnaptysBio currently has a consensus target price of $30.2857, indicating a potential upside of 45.12%. Odonate Therapeutics has a consensus target price of $19.3333, indicating a potential upside of 402.16%. Given Odonate Therapeutics' higher possible upside, analysts plainly believe Odonate Therapeutics is more favorable than AnaptysBio.

Summary

AnaptysBio beats Odonate Therapeutics on 7 of the 12 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and Odonate Therapeutics (NASDAQ:ODT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk & Volatility

Aldeyra Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, Odonate Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Institutional and Insider Ownership

61.3% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Odonate Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 48.9% of Odonate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aldeyra Therapeutics and Odonate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aldeyra TherapeuticsN/A-73.73%-52.74%
Odonate TherapeuticsN/A-85.75%-71.45%

Earnings and Valuation

This table compares Aldeyra Therapeutics and Odonate Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-5.87
Odonate TherapeuticsN/AN/A$-111,820,000.00($4.05)-0.95

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Odonate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Aldeyra Therapeutics and Odonate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aldeyra Therapeutics011002.91
Odonate Therapeutics13102.00

Aldeyra Therapeutics currently has a consensus target price of $26.00, indicating a potential upside of 115.95%. Odonate Therapeutics has a consensus target price of $19.3333, indicating a potential upside of 402.16%. Given Odonate Therapeutics' higher possible upside, analysts plainly believe Odonate Therapeutics is more favorable than Aldeyra Therapeutics.

Summary

Aldeyra Therapeutics beats Odonate Therapeutics on 7 of the 11 factors compared between the two stocks.

Marinus Pharmaceuticals (NASDAQ:MRNS) and Odonate Therapeutics (NASDAQ:ODT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk & Volatility

Marinus Pharmaceuticals has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Odonate Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Marinus Pharmaceuticals and Odonate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marinus Pharmaceuticals00903.00
Odonate Therapeutics13102.00

Marinus Pharmaceuticals currently has a consensus target price of $28.75, indicating a potential upside of 85.24%. Odonate Therapeutics has a consensus target price of $19.3333, indicating a potential upside of 402.16%. Given Odonate Therapeutics' higher possible upside, analysts plainly believe Odonate Therapeutics is more favorable than Marinus Pharmaceuticals.

Earnings and Valuation

This table compares Marinus Pharmaceuticals and Odonate Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($3.96)-3.92
Odonate TherapeuticsN/AN/A$-111,820,000.00($4.05)-0.95

Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Odonate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.3% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 96.0% of Odonate Therapeutics shares are held by institutional investors. 2.8% of Marinus Pharmaceuticals shares are held by company insiders. Comparatively, 48.9% of Odonate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Marinus Pharmaceuticals and Odonate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marinus PharmaceuticalsN/A-95.56%-66.01%
Odonate TherapeuticsN/A-85.75%-71.45%

Summary

Marinus Pharmaceuticals beats Odonate Therapeutics on 6 of the 11 factors compared between the two stocks.

Odonate Therapeutics (NASDAQ:ODT) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Odonate Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Odonate Therapeutics and Crinetics Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Odonate Therapeutics13102.00
Crinetics Pharmaceuticals01302.75

Odonate Therapeutics presently has a consensus target price of $19.3333, indicating a potential upside of 402.16%. Crinetics Pharmaceuticals has a consensus target price of $35.00, indicating a potential upside of 105.04%. Given Odonate Therapeutics' higher possible upside, analysts clearly believe Odonate Therapeutics is more favorable than Crinetics Pharmaceuticals.

Earnings & Valuation

This table compares Odonate Therapeutics and Crinetics Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Odonate TherapeuticsN/AN/A$-111,820,000.00($4.05)-0.95
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17

Crinetics Pharmaceuticals has higher revenue and earnings than Odonate Therapeutics. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Odonate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.0% of Odonate Therapeutics shares are owned by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are owned by institutional investors. 48.9% of Odonate Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Odonate Therapeutics and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Odonate TherapeuticsN/A-85.75%-71.45%
Crinetics PharmaceuticalsN/A-43.35%-39.73%

Summary

Crinetics Pharmaceuticals beats Odonate Therapeutics on 8 of the 12 factors compared between the two stocks.


Odonate Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Evolus logo
EOLS
Evolus
1.1$13.58+2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23+2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87+6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04+4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52+3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07+4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44+2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26+1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20+5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56+0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10+0.6%$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66+5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04+0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32+0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87+4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28+0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04+5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44+10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78+0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00+21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97+0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00+0.3%$502.28 million$58.12 million-16.28
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.72+1.2%$500.13 million$57.49 million-6.49
XBiotech logo
XBIT
XBiotech
1.0$16.95+0.4%$499.33 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87+0.6%$494.21 million$111.75 million-7.63
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.53+6.6%$494.19 millionN/A-2.59Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.90+1.7%$479.24 million$5.80 million-6.48
Akouos logo
AKUS
Akouos
1.6$13.87+1.4%$477.16 millionN/A0.00News Coverage
Verastem logo
VSTM
Verastem
1.1$2.76+1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07+3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48+2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.18+2.4%$469.72 million$6.68 million-5.04
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.06+3.3%$469.72 million$335 million-1.03Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.63+3.4%$466.82 million$56.50 million0.00Analyst Upgrade
Gap Up
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.57+4.1%$465.95 million$6.07 million-3.62Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23+0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
BCEL
Atreca
1.7$12.29+3.4%$452.65 millionN/A-4.36Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.29+3.1%$452.48 millionN/A0.00Gap Up
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.33+2.3%$449.56 million$102.31 million6.46
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.02+1.4%$446.29 millionN/A0.00News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8N/AN/A$439.81 millionN/A-3.55
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.92+3.9%$438.87 millionN/A-12.08News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$38.99+0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
Sesen Bio logo
SESN
Sesen Bio
1.2$2.52+3.2%$426.85 millionN/A-5.73Gap Down
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.45+0.4%$426.64 million$380,000.000.00Analyst Upgrade
DURECT logo
DRRX
DURECT
1.4$1.85+1.6%$420.32 million$29.56 million-36.99
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.66+0.6%$415.41 million$9.48 million-0.28
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$8.26+13.1%$407.75 million$2.42 million-7.25Analyst Report
Unusual Options Activity
Analyst Revision
Gap Up
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$8.12+2.2%$405.38 million$72.96 million-2.63Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.